Affordable Access

Angiotensin receptor blockers in heart failure.

Authors
  • Stergren, Jan
  • McMurray, John J V
Type
Published Article
Journal
Journal of the renin-angiotensin-aldosterone system : JRAAS
Publication Date
Sep 01, 2003
Volume
4
Issue
3
Pages
171–175
Identifiers
PMID: 14608522
Source
Medline
License
Unknown

Abstract

Collectively, a series of large, prospective randomised outcome trials has now shown that angiotensin receptor blockers (ARBs) are of clinical value in a broad spectrum of patients with symptomatic heart failure, regardless of background therapy and ventricular function. There is a clear benefit of ARBs in patients unable to tolerate an angiotensin- converting enzyme (ACE) inhibitor and this benefit is of a similar magnitude to that obtained with an ACE inhibitor (ACE-I). Both Val-HeFT and, particularly, CHARM-Added, also show that symptoms, morbidity and mortality are further reduced if an ARB is added to an ACE-I. This benefit is not only statistically significant but clinically important. CHARM-Preserved showed that candesartan can reduce hospital admission for heart failure in patients with preserved systolic function though more definitive outcome data are needed in this group.

Report this publication

Statistics

Seen <100 times